We can see the stock price rising significantly in 21 due to sale of PRX004 to NVO with potential royalties. And then the swale in mid 22 when all that remained was the promise of several Alzheimers candidates via both TAU and Ameloid targets. The company talks like it wants to become a full pharma and does not wish to be acquired.
So the only explanation I can see for a return from $25 up to $60 or so in Sept 22 was excitement over other's Alzheimers drug approvals. Yet it does seem that PRTA has a broad array of possible breakthroughs which are indeed exciting. Yet they needed another capital raise at $56 or so. That would suggest a need to keep pumping more money into R&D without much chance for early profits.
I did take a chance and sold a couple of $55 calls for $15 which have looked like they could expire worthless until yesterday's earnings report which must have jacked up listeners to the conference call since I don't see anything all that improved in the results. Today the price is up 6% while the markets overall are down a solid 1% apparently due to tough inflation numbers.
We could get a thrill with any approval but that is mostly hope as a strategy as far as I can see.